Working Paper: NBER ID: w28349
Authors: Maya M. Durvasula; Lisa Larrimore Ouellette; Heidi L. Williams
Abstract: Recent policy attention has focused on proposals to reduce prices for drugs that have received public funding. From an implementation perspective, such policies rely on public disclosure of government support for research. In this paper, we highlight two conceptual problems with past attempts to measure these public disclosures, and construct a new data set which corrects for these problems. Our corrected measures suggest that under-reporting of public research support is less of an issue than previously thought.
Keywords: biomedical research; public funding; drug pricing; patent disclosures
JEL Codes: I10; O30
Edges that are evidenced by causal inference methods are in orange, and the rest are in light blue.
| Cause | Effect |
|---|---|
| Public funding disclosures via certificates of correction (H79) | perceived completeness of reported public research support (I23) |
| Timing of corrections to patent disclosures (O38) | acknowledgment of government funding (H81) |
| Federal regulations (L51) | disclosure practices of patent holders (O34) |
| Corrections made to patent disclosures (Y20) | strategic behavior by applicants (C78) |